Hutchison China MediTech
Acceptance of surufatintib China NDA in epNETMereo BioPharma
Setrusumab set to advanceMaxCyte
Third cohort in CARMA Phase I initiatedNexstim
Warrants to be topped up with share placementNexstim
Q319 update shows therapy business momentumNexstim
A possible new opportunity in severe depressionMaxCyte
Editas deal marks sixth commercial licenceHutchison China MediTech
ESMO 2019: surufatinib epNET PFS benefit confirmedMereo BioPharma
Entering an important 12 month periodMaxCyte
Consistent solid delivery